Nurix Therapeutics, Inc.
NRIX
$13.59
$0.403.03%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -29.15% | -17.76% | 2.25% | 94.02% | 99.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.15% | -17.76% | 2.25% | 94.02% | 99.31% |
| Cost of Revenue | 17.17% | 10.01% | 5.96% | 3.29% | 2.52% |
| Gross Profit | -48.97% | -26.31% | -7.78% | 22.71% | 23.11% |
| SG&A Expenses | 7.09% | 10.89% | 10.58% | 16.30% | 12.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.31% | 10.17% | 6.79% | 5.52% | 4.29% |
| Operating Income | -37.38% | -22.27% | -8.47% | 14.53% | 15.67% |
| Income Before Tax | -34.28% | -18.83% | -4.69% | 18.99% | 20.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.47% | -19.01% | -4.81% | 18.94% | 20.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.47% | -19.01% | -4.81% | 18.94% | 20.19% |
| EBIT | -37.38% | -22.27% | -8.47% | 14.53% | 15.67% |
| EBITDA | -37.65% | -22.31% | -7.92% | 15.77% | 17.13% |
| EPS Basic | -9.10% | -5.94% | 1.63% | 24.90% | 28.94% |
| Normalized Basic EPS | -8.93% | -5.78% | 1.73% | 24.94% | 28.94% |
| EPS Diluted | -9.10% | -5.94% | 1.63% | 24.90% | 28.94% |
| Normalized Diluted EPS | -8.93% | -5.78% | 1.73% | 24.94% | 28.94% |
| Average Basic Shares Outstanding | 23.52% | 12.98% | 6.21% | 7.11% | 11.80% |
| Average Diluted Shares Outstanding | 23.52% | 12.98% | 6.21% | 7.11% | 11.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
